You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 27, 2024

Investigational Drug Information for tomivosertib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug tomivosertib?

tomivosertib is an investigational drug.

There have been 6 clinical trials for tomivosertib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 25th 2018.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Effector Therapeutics, Stand Up To Cancer, and Translational Research in Oncology.

There are two US patents protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for tomivosertib
TitleSponsorPhase
Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive ChemotherapyNational Cancer Institute (NCI)Phase 1
Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive ChemotherapyNorthwestern UniversityPhase 1
Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 TherapyMedpace, Inc.Phase 2

See all tomivosertib clinical trials

Clinical Trial Summary for tomivosertib

Top disease conditions for tomivosertib
Top clinical trial sponsors for tomivosertib

See all tomivosertib clinical trials

US Patents for tomivosertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
tomivosertib ⤷  Sign Up Inhibitors of immune checkpoint modulators and related methods eFFECTOR Therapeutics Inc. (San Diego, CA) ⤷  Sign Up
tomivosertib ⤷  Sign Up Methods and compositions for cellular immunotherapy eFFECTOR Therapeutics Inc. (San Diego, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for tomivosertib

Drugname Country Document Number Estimated Expiration Related US Patent
tomivosertib Canada CA3064000 2037-05-24 ⤷  Sign Up
tomivosertib World Intellectual Property Organization (WIPO) WO2018218038 2037-05-24 ⤷  Sign Up
tomivosertib Australia AU2015279984 2034-06-25 ⤷  Sign Up
tomivosertib Brazil BR112016029916 2034-06-25 ⤷  Sign Up
tomivosertib Canada CA2953365 2034-06-25 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.